ACE Inhibition But Not Angiotensin II Antagonism Reduces Plasma Fibrinogen and Insulin Resistance in Overweight Hypertensive Patients
- 1 October 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 32 (4) , 616-620
- https://doi.org/10.1097/00005344-199810000-00014
Abstract
The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients. Twenty-eight overweight mild to moderate [diastolic blood pressure (DBP) >90 and <110 mm Hg] hypertensives aged 43-64 years, after a 4-week placebo period, were randomized to perindopril, 4 mg o.d., or losartan, 50 mg o.d., for 6 weeks. Then, after a new placebo period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the treatment periods, blood pressure was measured, plasma fibrinogen was evaluated, and insulin sensitivity was assessed by the euglycemic, hyperinsulinemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Both perindopril and losartan reduced SBP (by a mean of 20.2 mm Hg, p < 0.001 vs. placebo; and 15.8 mm Hg, p = 0.002 vs. placebo, respectively) and DBP (by a mean of 15.2 mm Hg, p = 0.001 vs. placebo, and 11.8 mm Hg, p = 0.01 vs. placebo respectively), with no difference between the two treatments. GIR was significantly increased by perindopril (+2.91 mg/min/kg, p = 0.042 vs. placebo), but not by losartan (+0.28 mg/min/kg, NS). TGR was not modified by losartan but was increased by perindopril (+9.3 g, p = 0.042 vs. placebo). Plasma fibrinogen levels were reduced by perindopril (−53.4 mg/dl, p = 0.022 vs. placebo) but not by losartan (−16.8 mg/dl, NS). The perindopril-induced decrease in fibrinogen was correlated with the increase in GIR (r = 0.39; p < 0.01). These findings suggest that fibrinogen decrease produced by the ACE inhibitor is related to its action on insulin sensitivity, which seems to be dependent not on angiotensin II blockade but rather on other mechanisms.Keywords
This publication has 28 references indexed in Scilit:
- Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in SwedenJournal Of Hypertension, 1997
- 72. Involvement of the haemostatic system in the insulin resistance syndrome (IRS)Fibrinolysis, 1996
- Impaired fibrinolysis and insulin resistance in patients with hypertensionAmerican Journal of Hypertension, 1996
- Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertensionAmerican Journal of Hypertension, 1995
- Insulin resistance, compensatory hyperinsulinaemia, and coronary heart diseaseDiabetologia, 1994
- Improved Insulin Action and Glycemic Control After Long Term Angiotensin-Converting Enzyme Inhibition in Subjects with Arterial Hypertension and Type II DiabetesDiabetes Care, 1993
- Antihypertensive TherapyJournal of Cardiovascular Pharmacology, 1992
- Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular diseaseJournal of Internal Medicine, 1990
- Insulin Sensitivity in Newly Detected Hypertensive PatientsJournal of Cardiovascular Pharmacology, 1990
- Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1987